E Transpharma
E Transpharma
E Transpharma
#1 2690
CFO 330
Collections from credit customers 6,170 6,170
Interest from short‐term investments 200 200
Fees received in advance 1,680 1,680
Payments of materials and supplies 1,590 - 1,590
Interest on borrowings 160 - 160
Payments for salaries and other operating costs 7,430 - 7,430
Corporate income tax 40 - 40
External funding of product development under royalty‐shari 1,500
CFI - 640
Purchase of property and equipment 870 - 870
Sale of short‐term investments 230 230 CFO
CFF 1,470
Share issue 2,670 2,670
Repayment of borrowings 1,200 - 1,200
1,160
Final 3,850
#3
Financing through shareholders
Still investing in equipment
4#
Operation show losses on cash - operation is losing money not generating it
Payments 11,290 1,160
Purchase of property and equipment 870 870 CFI
Repayment of borrowings 1,200 1,200 CFF
Payments of materials and supplies 1,590 1,590 CFO
Interest on borrowings 160 160 CFO
Payments for salaries and other operating costs 7,430 7,430 CFO
Corporate income tax 40 40 CFO
#2 X4
Fixed assets 4,760
CFO Property, plant & equipment, net 4,760
610
Current assets 8,200
Inventories 130
Accounts receivable 2,190
Short‐term investments 2,030
Cash 3,850
CFO CFI
Operating liabilities 350
Operating assets other than cash -690
Non operating rev -10
Non operation losses
Taxes -20
Depreciation 610
Net income 90
330 330
0 -870
230
0
Purchase -870
Selling 30 230
Depreciation 610
0
Depreciation -610
Buy 870
260
X3
4,500 260 Shareholders’ equity 7,800
4,500 260 Share capital and premium 9,470
Accumulated losses - 1,670
6,570 1630
230 -100 Current liabilities 5,160
1,400 790 Short‐term borrowings** 2,000
2,250 -220 Accts payable, materials & supplies 340
2,690 1160 Fees received in advance 1,500
Accrued salaries and other 1,230
11,070 1890 Taxes payable 90
Shareholders’ equity
Share capital and premium
Accumulated losses
Current liabilities
Short‐term borrowings**
Accts payable, materials & supplies
Fees received in advance
Accrued salaries and other
Taxes payable
5,040 2,760
6,800 2,670
- 1,760 90
11,070 1890
610 -870
100
-790
-10 230
2,670
90 -1200
-30
240
140
-20
#1 2690
CFO 330
Collections from credit customers 6,170 6,170
Interest from short‐term investments 200 200
Fees received in advance 1,680 1,680
Payments of materials and supplies 1,590 - 1,590
Interest on borrowings 160 - 160
Payments for salaries and other operating costs 7,430 - 7,430
Corporate income tax 40 - 40
External funding of product development under royalty‐shari 1,500
CFI - 640
Purchase of property and equipment 870 - 870
Sale of short‐term investments 230 230 CFO
CFF 1,470
Share issue 2,670 2,670
Repayment of borrowings 1,200 - 1,200
1,160
Final 3,850
#3
Financing through shareholders
Still investing in equipment
4#
Operation show losses on cash - operation is losing money not generating it
Payments 11,290 1,160
Purchase of property and equipment 870 870 CFI
Repayment of borrowings 1,200 1,200 CFF
Payments of materials and supplies 1,590 1,590 CFO
Interest on borrowings 160 160 CFO
Payments for salaries and other operating costs 7,430 7,430 CFO
Corporate income tax 40 40 CFO
#2 X4
Fixed assets 4,760
CFO Property, plant & equipment, net 4,760
610
Current assets 8,200
Inventories 130
Accounts receivable 2,190
Short‐term investments 2,030
Cash 3,850
CFO CFI
Operating liabilities -850
Operating assets other than cash 470
Non operating rev -10
Non operation losses
Taxes 20
Depreciation 610
Net income 90
330 330
-260
0
Purchase -870
Selling 30 230
Depreciation 610
0
X3
4,500 260 Shareholders’ equity 7,800 5,040 2,760
4,500 260 Share capital and premium 9,470 6,800 2,670
Accumulated losses - 1,670 - 1,760 90
6,570 1630
230 -100 Current liabilities 5,160 6,030 -870 760
1,400 790 Short‐term borrowings** 2,000 3,200 -1200
2,250 -220 Accts payable, materials & supplies 340 370 -30
2,690 1160 Fees received in advance 1,500 1,260 240
Accrued salaries and other 1,230 1,090 140
11,070 1890 Taxes payable 90 110 -20
610
870
260
-1200
2670